Albumin is a colloidal protein, plasma expander which plays an important role in regulation of blood circulation volume, and is the most protein in blood plasma, 55-60% of total plasma protein. Decreased albumin levels (hypoalbuminemia) can cause a decrease in the synthesis and increase of albumin destruction/loss that endangers the lives of sufferers, and impaired fluid balance/oncotic pressure in the body, so that albumin is used as a therapy in conditions of hypoalbuminemia. Albumin is an expensive drug that is associated with limitations in the market and difficulties in the production process, so its use is a controversial issue. This study aims to assess the cost of using albumin by looking at an overview of direct medical costs in patients receiving albumin therapy and seeing whether there are significant differences in the cost of using albumin in a variety of patient conditions. This research uses descriptive observational method with cross-sectional research design. Data collection began in November-December 2018 conducted retrospectively by looking at patient data in the Medical Record and Hospital Management Information System. The total population in this study was 75 patients and then total sampling was carried out. Data analysis in this study used descriptive analysis and for the diagnosis group with a number of patients at least 3 Kruskal-Wallis non-parametric statistics were conducted to determine whether there were differences in the cost of using albumin in various conditions. The results of this study indicate that the diagnosis of patients receiving albumin therapy (at least 3 patients) is stroke, diabetes mellitus, sepsis, cerebral infarction, neoplasm, impaired plasma protein metabolism, pneumonia, congestive heart failure, and anemia. The picture of direct medical costs in patients who get albumin therapy is greatest in the diagnosis of neoplasms with an average total direct medical costs of Rp.76,929,989,- which includes the cost of hospitalization, drug costs, hospital facility costs, laboratory costs, fees other health, doctor fees, and visite fees. The results of analysis the cost of albumin data on various patient conditions indicate that there is no significant difference in the cost of albumin use in various patient conditions (p> 0.05), so that the efficiency of using albumin therapy can be more focused on the patient's clinical effectiveness and outcome.